<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00267865</url>
  </required_header>
  <id_info>
    <org_study_id>060051</org_study_id>
    <secondary_id>06-C-0051</secondary_id>
    <nct_id>NCT00267865</nct_id>
    <nct_alias>NCT00304044</nct_alias>
  </id_info>
  <brief_title>Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma</brief_title>
  <official_title>AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will investigate the use of chemotherapy plus highly active antiretroviral therapy
      (HAART) in patients with AIDS-related primary brain lymphoma. None of the drugs used in this
      study are experimental, but chemotherapy plus HAART has not been established as a standard
      treatment in patients with AIDS. The chemotherapy regimen used in this study (see below) was
      chosen because it may be less toxic to immune cells called T-lymphocytes than most drug
      treatments for lymphoma.

      People with AIDS 18 and older and have primary brain lymphoma may be eligible for this study.
      Candidates are screened with a medical history and physical examination, MRI, CT and PET
      scans, cerebrospinal fluid studies, brain biopsy at tumor sites, if possible,
      electrocardiogram and blood tests.

      Participants undergo six 2-week &quot;induction treatment&quot; cycles of HAART plus chemotherapy with
      methotrexate, rituximab and leucovorin, followed by two 4-week &quot;consolidation&quot; treatment
      cycles using HAART, methotrexate and leucovorin, and then HAART alone. Rituximab is given by
      intravenous (IV, through a vein) day 1 of each cycle. Also on day 1 IV fluids are given to
      lower acidity in the urine to protect the kidneys from the methotrexate. On day 2,
      methotrexate is infused through a vein over 4 hours. Starting 24 hours after initiation of
      the methotrexate infusion, leucovorin is given every 3 to 6 hours (first IV and then possibly
      by mouth) until the drug decreases to a target level in the blood. HAART is begun as soon as
      possible. The specific HAART regimen for each patient is determined individually. All
      patients are hospitalized the first week of every 2-week treatment cycle for safety
      monitoring. In addition to HAART and chemotherapy, patients undergo the following tests and
      procedures:

        -  Intellectual functioning: Before starting treatment, patients are tested for their
           ability to understand basic concepts and coordination in order to be able to evaluate
           how the brain lymphoma affects thinking and concentration. After the lymphoma appears to
           have resolved, more formal and intensive tests are done. The intensive tests are
           repeated each year, and shorter, interim tests are done about every 6 months. Also, a
           specialist periodically monitors patients' understanding of HAART and the importance of
           this therapy.

        -  Blood tests: Blood is drawn every day during hospitalizations to measure methotrexate
           levels and to evaluate kidney and liver function and blood counts. Blood is also drawn
           before starting therapy, when the lymphoma disappears, 6 months after completing
           treatment, and any time it appears that the lymphoma may have recurred to test for
           Epstein-Barr virus (EBV), a virus that is almost always present in AIDS-related primary
           brain lymphoma.

        -  Imaging tests: Patients undergo magnetic resonance imaging (MRI) and positron emission
           tomography (PET) scans periodically to monitor the effects of treatment on the lymphoma.
           MRI scans are done after the 2nd, 4th, 6th, and 8th treatments, then every 2 months for
           three times, every 3 months for six times, every 6 months for four times, and then every
           year for 5 years, or sooner if there is a concern about the brain. PET scans are done
           after the first cycle, after the MRI suggests the lymphoma is gone, and then yearly.

        -  Lumbar puncture (spinal tap): This test is done to look for EBV in the cerebrospinal
           fluid (CSF). Under local anesthetic, a needle is inserted in the space between the bones
           in the lower back where the CSF circulates below the spinal cord and a small amount of
           fluid is collected through the needle. This test is done at the same times as the blood
           tests for EBV.

        -  Eye examinations: Patients' eyes are examined periodically because brain lymphoma can
           sometimes spread to the eye and because some people with AIDS-related primary brain
           lymphoma are at risk of certain eye infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: AIDS-related primary central nervous system lymphoma (AR-PCNSL) is an
      Epstein-Barr virus (EBV)-driven lymphoproliferative process that typically results in death
      within a few months. Essentially all of the cases are immunoblastic CD20+ tumors, and occur
      once the CD4+ cells have fallen to below 50 cells/mm^3. Highly active antiretroviral therapy
      (HAART) can result in immune reconstitution that decreases the risk of AR-PCNSL. However, a
      subset of HIV-infected patients still develops ARPCNSL, often because they are unaware that
      they are HIV infected, or they do not take HAART. Treatment options for such patients are
      limited. In the non-AIDS setting, chemotherapy has become the standard of care for primary
      central nervous system lymphoma (PCNSL) and late neurocognitive decline consequent to
      radiotherapy can be avoided by such approaches. In the pre-HAART era, AR-PCNSL was generally
      treated with whole brain radiotherapy, however death due to recurrent lymphoma or to other
      AIDS complications occurred prior to the potential manifestations of late occurring
      radiation-related neurotoxicity. Radiation-sparing approaches have not been studied in
      AR-PCNSL in the HAART era, where advances in antiretroviral therapy have made curative intent
      chemotherapy feasible for most patients with HIV infection.

      Objectives: The primary objective of this study is to estimate the fraction of patients with
      AR-PCNSL receiving experimental treatment consisting of HAART, combined with rituximab,
      high-dose methotrexate and leucovorin (R-HD-MTX) who are alive and without recurrent lymphoma
      or severe cognitive problems at two years. .

      Eligibility: HIV-infected, age 18 years or older, AR-PCSNL that has not previously been
      treated, and be able to give informed consent or have a durable power of attorney who can
      provide informed consent, HIV profile that makes them likely to respond to HAART. There are a
      number of other specific inclusion and exclusion criteria, in part to exclude patients who
      would be unlikely to tolerate the therapy.

      Design: Phase II pilot study investigating R-HD-MTX given with leucovorin rescue and HAART as
      a treatment for AR-PCNSL. Evaluation will include quantitative measurement of lymphocyte
      subsets, quantitative polymerase chain reaction (PCR) of HIV and EBV viral loads (including
      both blood and cerebrospinal fluid in the case of EBV) to assess immune response and
      anti-viral effects. Tumor evaluation with brain magnetic resonance imaging (MRI) and brain
      fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET scans) will be used for
      staging and response assessment. Longitudinal neuropsychologic testing after complete
      responses are documented will serve to evaluate neurocognitive parameters post therapy.

      a separate cohort for additional secondary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 16, 2005</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival; without recurrent lymphoma or severe cognitive problems at two years</measure>
    <time_frame>2 years</time_frame>
    <description>number of patients alive at 2 years without recurrent brain lymphoma or severe neurocognitive defects</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Lymphoma-AIDS-Related</condition>
  <condition>Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>6000 mg/m2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patient s urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 IV day 1 of each cycle prior to administration of high-dose methotrexate</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin calcium doses will be administered orally or by short IV infusion over 15 minutes</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Positive HIV serology (previous records acceptable)

          -  Diagnosis of Primary Central Nervous System Lymphoma

          -  Confirmed histopathologic diagnosis by NCI Laboratory of Pathology

          -  If tissue diagnosis is not feasible for any reason, such as undue risk to the patient
             to acquire tissue diagnosis, the following will be accepted as confirmed AR-PCNSL
             diagnosis:

          -  Positive brain FDG-PET and

          -  EBV detected in the CSF using PCR

          -  Age 18 years or greater

          -  ECOG performance less than or equal to 0-4

          -  Ability to understand and willing to provide informed consent

          -  If patient unable to understand informed consent, a previously designated durable
             power of attorney for healthcare or an individual with legal authority may substitute
             in this capacity

          -  Assignment of a durable power of attorney for healthcare if not already done

        EXCLUSION CRITERIA:

          -  Prior therapy for CNS lymphoma

          -  Steroids not an exclusion

          -  Evidence of lymphoma outside of the central nervous system

          -  Ocular involvement will not exclude

          -  Multidrug resistant HIV not amenable to long-term suppression based on either or both:

          -  Clinical history of poor adherence to multiple antiretroviral drugs deemed sufficient
             to render effective HIV control unattainable;

          -  HIV mutational analysis (genotyping and/or phenotyping) that reveals high-level
             resistance to more than 1 class of anti-HIV drugs such that a combination regimen
             comprised of agents from at least two drug classes can not be devised to suppress HIV
             long-term.

          -  Refusal to adhere to HAART

          -  Concurrent malignancy other than Kaposi sarcoma, resectable squamous cell or basal
             cell skin cancer, or T1 anal cancer amenable to surgical resection.

          -  Heart failure, Class IV by New York Heart Association criteria

          -  Chronic Liver Disease, Child-Pugh class B or C

        Pregnancy

          -  Refusal to practice contraception during chemotherapy.

          -  Any condition or set of circumstances that the Principal Investigator or Protocol
             Chair interprets as creating undue risk to the patient by participating on this study
             or would make the patient unlikely to comply with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Yarchoan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anaida Widell</last_name>
    <phone>(301) 451-3694</phone>
    <email>awidell@cc.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Yarchoan, M.D.</last_name>
    <phone>(240) 760-6075</phone>
    <email>robert.yarchoan@nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact National Cancer Institute Referral Office</last_name>
      <phone>(888) NCI-1937</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2006-C-0051.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Levine AM. AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97. Review.</citation>
    <PMID>8350362</PMID>
  </reference>
  <reference>
    <citation>Goplen AK, Dunlop O, Liest√∏l K, Lingjaerde OC, Bruun JN, Maehlen J. The impact of primary central nervous system lymphoma in AIDS patients: a population-based autopsy study from Oslo. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 1;14(4):351-4.</citation>
    <PMID>9111477</PMID>
  </reference>
  <reference>
    <citation>von Gunten CF, Von Roenn JH. Clinical aspects of human immunodeficiency virus-related lymphoma. Curr Opin Oncol. 1992 Oct;4(5):894-9. Review.</citation>
    <PMID>1457504</PMID>
  </reference>
  <verification_date>March 21, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2005</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS-Related-Primary Central Nervous System Lymphoma</keyword>
  <keyword>High Dose Methotrexate</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Highly Active Antiretroviral Therapy</keyword>
  <keyword>AIDS Related-Primary Central Nervous System Lymphoma</keyword>
  <keyword>AR-PCNSL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

